SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-20-095232
Filing Date
2020-04-02
Accepted
2020-04-02 06:07:35
Documents
1
Group Members
COLUMN GROUP GP, LPCOLUMN GROUP II GP, LPCOLUMN GROUP II, LPCOLUMN GROUP III GP, LPCOLUMN GROUP III, LPCOLUMN GROUP III-A, LPCOLUMN GROUP MANAGEMENT, LPDAVID V. GOEDDELPETER SVENNILSONPONOI CAPITAL II, LPPONOI CAPITAL, LPPONOI II MANAGEMENT, LLCPONOI MANA

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d908610dsc13da.htm SC 13D/A 266543
  Complete submission text file 0001193125-20-095232.txt   268511
Mailing Address 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158 415-865-2050
COLUMN GROUP L P (Filed by) CIK: 0001347769 (see all company filings)

IRS No.: 000000000
Type: SC 13D/A

Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Subject) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90978 | Film No.: 20767291
SIC: 2834 Pharmaceutical Preparations